267 related articles for article (PubMed ID: 38035547)
41. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
[TBL] [Abstract][Full Text] [Related]
42. Measurable residual disease study through three different methods can anticipate relapse and guide pre-emptive therapy in childhood acute myeloid leukemia.
Ramos Elbal E; Fuster JL; Campillo JA; Galera AM; Cortés MB; Llinares ME; Jiménez I; Plaza M; Banaclocha HM; Galián JA; Blanquer Blanquer M; Martínez Sánchez MV; Muro M; Minguela A
Clin Transl Oncol; 2023 May; 25(5):1446-1454. PubMed ID: 36598635
[TBL] [Abstract][Full Text] [Related]
43. Minimal residual disease in acute myelogenous leukemia.
Cruz NM; Mencia-Trinchant N; Hassane DC; Guzman ML
Int J Lab Hematol; 2017 May; 39 Suppl 1(Suppl 1):53-60. PubMed ID: 28447422
[TBL] [Abstract][Full Text] [Related]
44. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].
Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363
[TBL] [Abstract][Full Text] [Related]
45. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.
Heuser M; Freeman SD; Ossenkoppele GJ; Buccisano F; Hourigan CS; Ngai LL; Tettero JM; Bachas C; Baer C; Béné MC; Bücklein V; Czyz A; Denys B; Dillon R; Feuring-Buske M; Guzman ML; Haferlach T; Han L; Herzig JK; Jorgensen JL; Kern W; Konopleva MY; Lacombe F; Libura M; Majchrzak A; Maurillo L; Ofran Y; Philippe J; Plesa A; Preudhomme C; Ravandi F; Roumier C; Subklewe M; Thol F; van de Loosdrecht AA; van der Reijden BA; Venditti A; Wierzbowska A; Valk PJM; Wood BL; Walter RB; Thiede C; Döhner K; Roboz GJ; Cloos J
Blood; 2021 Dec; 138(26):2753-2767. PubMed ID: 34724563
[TBL] [Abstract][Full Text] [Related]
46. Time point-dependent concordance and prognostic significance of flow cytometry and real time quantitative PCR for measurable/minimal residual disease detection in acute myeloid leukemia with t(8;21)(q22;q22.1).
Shang L; Cai X; Sun W; Cheng Q; Mi Y
Cytometry B Clin Cytom; 2022 Jan; 102(1):34-43. PubMed ID: 34232569
[TBL] [Abstract][Full Text] [Related]
47. Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity.
Bazinet A; Kadia T; Short NJ; Borthakur G; Wang SA; Wang W; Loghavi S; Jorgensen J; Patel K; DiNardo C; Daver N; Alvarado Y; Haddad FG; Pierce S; Nogueras Gonzalez G; Maiti A; Sasaki K; Yilmaz M; Thompson P; Wierda W; Garcia-Manero G; Andreeff M; Jabbour E; Konopleva M; Huang X; Kantarjian H; Ravandi F
Blood Adv; 2023 Jul; 7(13):3284-3296. PubMed ID: 36884300
[TBL] [Abstract][Full Text] [Related]
48. Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia.
Zeijlemaker W; Kelder A; Cloos J; Schuurhuis GJ
Curr Protoc Cytom; 2019 Dec; 91(1):e66. PubMed ID: 31763792
[TBL] [Abstract][Full Text] [Related]
49. Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study.
Zaliova M; Zuna J; Winkowska L; Janotova I; Skorepova J; Lukes J; Meyer C; Marschalek R; Novak Z; Domansky J; Stary J; Sramkova L; Trka J
Leukemia; 2024 Jan; 38(1):21-30. PubMed ID: 38001170
[TBL] [Abstract][Full Text] [Related]
50. SOHO State of the Art Updates and Next Questions: Pre-emptive Therapy at Molecular Measurable Residual Disease Failure in Acute Myeloid Leukemia.
Tedjaseputra A; Russell N; Dillon R
Clin Lymphoma Myeloma Leuk; 2024 Mar; ():. PubMed ID: 38734498
[TBL] [Abstract][Full Text] [Related]
51. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
[TBL] [Abstract][Full Text] [Related]
52. Measurable residual disease testing for personalized treatment of acute myeloid leukemia.
Ehinger M; Pettersson L
APMIS; 2019 May; 127(5):337-351. PubMed ID: 30919505
[TBL] [Abstract][Full Text] [Related]
53. Genomic breakpoint-specific monitoring of measurable residual disease in pediatric non-standard-risk acute myeloid leukemia.
Maurer-Granofszky M; Kohrer S; Fischer S; Schumich A; Nebral K; Larghero P; Meyer C; Mecklenbrauker A; Muhlegger N; Marschalek R; Haas OA; Panzer-Grumayer R; Dworzak MN
Haematologica; 2024 Mar; 109(3):740-750. PubMed ID: 37345487
[TBL] [Abstract][Full Text] [Related]
54. Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia.
Dillon LW; Higgins J; Nasif H; Othus M; Beppu L; Smith TH; Schmidt E; Valentine Iii CC; Salk JJ; Wood BL; Erba HP; Radich JP; Hourigan CS
Haematologica; 2024 Feb; 109(2):401-410. PubMed ID: 37534515
[TBL] [Abstract][Full Text] [Related]
55. Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study.
Rosso A; Juliusson G; Lorenz F; Lehmann S; Derolf Å; Deneberg S; Jädersten M; Antunovic P; Cammenga J; Möllgård L; Wennström L; Ölander E; Ehinger M; Fogelstrand L; Höglund M; Lazarevic VL
Leuk Lymphoma; 2021 Aug; 62(8):1973-1981. PubMed ID: 33719843
[TBL] [Abstract][Full Text] [Related]
56. Development of a Next-generation Sequencing-based Gene Panel Test to Detect Measurable Residual Disease in Acute Myeloid Leukemia.
Kim JJ; Jang JE; Lee HA; Park MR; Kook HW; Lee ST; Choi JR; Min YH; Shin S; Cheong JW
Ann Lab Med; 2023 Jul; 43(4):328-336. PubMed ID: 36843401
[TBL] [Abstract][Full Text] [Related]
57. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
Al-Mawali A; Gillis D; Lewis I
Am J Clin Pathol; 2009 Jan; 131(1):16-26. PubMed ID: 19095561
[TBL] [Abstract][Full Text] [Related]
58. A mind map for managing minimal residual disease in acute myeloid leukemia.
Benton CB; Ravandi F
Clin Adv Hematol Oncol; 2017 Nov; 15(11):859-867. PubMed ID: 29200419
[TBL] [Abstract][Full Text] [Related]
59. Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations.
Deng DX; Zhu HH; Liu YR; Chang YJ; Ruan GR; Jia JS; Jiang H; Jiang Q; Zhao XS; Huang XJ
Leuk Lymphoma; 2019 Sep; 60(9):2181-2189. PubMed ID: 30773106
[TBL] [Abstract][Full Text] [Related]
60. Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning.
Gronlund JK; Veigaard C; Juhl-Christensen C; Skou AS; Melsvik D; Ommen HB
Eur J Haematol; 2024 Apr; 112(4):601-610. PubMed ID: 38197567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
